Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 34407542

A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Blood
Publication date
2021 Nov 25
First author
Réa D

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Blood. 2021 Nov 25;138(21):2009-2010. doi: 10.1182/blood.2021013257.
    note
    Source null
    related pmid
    34821938
    relationship
    Comment in

Authors and identifiers

  1. name
    Réa D
    type
    Author
  2. name
    Mauro MJ
    type
    Author
  3. name
    Boquimpani C
    type
    Author
  4. name
    Minami Y
    type
    Author
  5. name
    Lomaia E
    type
    Author
  6. name
    Voloshin S
    type
    Author
  7. name
    Turkina A
    type
    Author
  8. name
    Kim DW
    type
    Author
  9. name
    Apperley JF
    type
    Author
  10. name
    Abdo A
    type
    Author
  11. name
    Fogliatto LM
    type
    Author
  12. name
    Kim DDH
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Réa D
    type
    Author
  2. name
    Mauro MJ
    type
    Author
  3. name
    Boquimpani C
    type
    Author
  4. name
    Minami Y
    type
    Author
  5. name
    Lomaia E
    type
    Author
  6. name
    Voloshin S
    type
    Author
  7. name
    Turkina A
    type
    Author
  8. name
    Kim DW
    type
    Author
  9. name
    Apperley JF
    type
    Author
  10. name
    Abdo A
    type
    Author
  11. name
    Fogliatto LM
    type
    Author
  12. name
    Kim DDH
    type
    Author
bibliography ids
  1. nci-bib-8e16a225e74985d65c5fd873
book metadata
content sha256
765ab452c61b3cfd9ad0278b13f537a4cb20be56dd1ad799416aa1c58ff4fe9a
document type
citation
dois
  1. 10.1182/blood.2020009984
electronic publication date
display
Source null
precision
missing
year
Source null
evidence scope
bibliographic_metadata_only
id
pubmed:34407542
immutable id
pubmed:34407542@765ab452c61b3cfd9ad0278b13f537a4cb20be56dd1ad799416aa1c58ff4fe9a
journal
abbreviation
Blood
issn electronic
1528-0020
issn print
0006-4971
issue
21
name
Blood
nlm unique id
7603509
pages
2031-2041
volume
138
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Blood. 2021 Nov 25;138(21):2009-2010. doi: 10.1182/blood.2021013257.
    note
    Source null
    related pmid
    34821938
    relationship
    Comment in
outcomes validated
false
pmid
34407542
provenance
batch id
192b6392c165c6b06274
provider
NCBI PubMed ESummary
record sha256
6d82fd8330c9068ecc4fbe052dcc26005a1310ace0779cfd2b509c297fccff6d
response sha256
7d81e9fb11ee99e6ad4116aecd61ba71cd6bf76f2a8f8f6d15c5c85e9c6c56b4
retrieved at
2026-09-09T23:48:02.713075+00:00
publication date
display
2021 Nov 25
precision
day
year
2021
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Randomized Controlled Trial
  4. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/34407542/
title
A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs.

Preserved source evidence · Not medical advice